Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
01 mars 2023 16h05 HE
|
Aprea Therapeutics
DOYLESTOWN, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic...
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
27 févr. 2023 16h05 HE
|
Aprea Therapeutics
DOYLESTOWN, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic...
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
22 févr. 2023 20h41 HE
|
Aprea Therapeutics
DOYLESTOWN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic...
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
22 févr. 2023 16h05 HE
|
Aprea Therapeutics
DOYLESTOWN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic...
Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)
15 févr. 2023 08h00 HE
|
Aprea Therapeutics
DOYLESTOWN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics...
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
13 févr. 2023 07h00 HE
|
Aprea Therapeutics
DOYLESTOWN, Pa., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer...
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
30 janv. 2023 08h00 HE
|
Aprea Therapeutics
DOYLESTOWN, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics...
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit
19 janv. 2023 08h00 HE
|
Aprea Therapeutics
DOYLESTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics...
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
11 janv. 2023 08h00 HE
|
Aprea Therapeutics
DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics...
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations
09 nov. 2022 16h15 HE
|
Aprea Therapeutics
BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer...